The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.
In a randomized trial of more than 2,500 patients at high cardiovascular risk, obicetrapib significantly reduced low-density lipoprotein cholesterol levels when added to existing lipid-lowering therapy.
ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.
A new guideline recommends using lifestyle interventions as first-line treatment to prevent, manage, and potentially reverse type 2 diabetes and prediabetes, supported by extensive clinical evidence.
Finerenone plus empagliflozin reduced urinary albumin-to-creatinine ratio by 29% to 32% more than either drug alone in patients with chronic kidney disease and type 2 diabetes.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A national study of 1.38 million emergency general surgery cases found that one frailty scoring system predicted mortality and complications more accurately than others.
A large population study found that higher dietary fiber intake was associated with reduced risk of stroke and improved survival among stroke survivors, with genetic evidence supporting a causal link for small vessel stroke.
A study of 32,960 hospitalizations finds 10.9% of patients with RSV experienced acute cardiovascular events, with significantly higher adjusted odds than boosted and unboosted COVID-19 cases.